Cargando…
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy
Paclitaxel (Taxol(®)) is a member of the taxane class of anticancer drugs and one of the most common chemotherapeutic agents used against many forms of cancer. Paclitaxel is a microtubule-stabilizer that selectively arrests cells in the G2/M phase of the cell cycle, and found to induce cytotoxicity...
Autores principales: | Barbuti, Anna Maria, Chen, Zhe-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695897/ https://www.ncbi.nlm.nih.gov/pubmed/26633515 http://dx.doi.org/10.3390/cancers7040897 |
Ejemplares similares
-
Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022) -
Targeted delivery of paclitaxel by functionalized selenium nanoparticles for anticancer therapy through ROS-mediated signaling pathways
por: Gong, Guifang, et al.
Publicado: (2018) -
Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma
por: Roy, Amit, et al.
Publicado: (2021) -
Editorial: Novel biomarkers for anticancer therapy
por: Wang, Ting, et al.
Publicado: (2023) -
Dual roles of SAMHD1 in tumor development and chemoresistance to anticancer drugs
por: Chen, Zhangming, et al.
Publicado: (2021)